BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Sep 17, 2007
 |  BioCentury  |  Analyst Picks & Changes

Analyst picks & changes

Analyst picks & changes

Analyst picks & changes
Company Bank Analyst Coverage Opinion Wk chg 9/14 cls
Alnylam (ALNY) Cantor Fitzgerald Pamela Bassett Upgrade Buy (from hold) 4% $27.99
Bassett raised her target to $32 from $20 after ALNY formed Regulus, a JV with Isis (ISIS) to discover, develop and commercialize miRNA therapeutics. She believes ALNY's consolidation of its miRNA technology platform into the JV will strengthen ALNY's position in RNAi and allow the company's development and licensing programs to undergo a robust period of expansion (see "Make Microlove, Not War," A9).
Amylin (AMLN) Lazard Matthew Osborne Upgrade Buy (from hold) 2% $49.02
Osborne set a target of $58. He expects high demand from endocrinologists for Byetta exenatide LAR in combination with metformin to treat Type II diabetes, and believes 2012 revenues for the long-acting release (LAR) formulation of synthetic exendin-4 could reach $2.8B in the U.S. and $4.2B worldwide.
ArQule (ARQL) Lazard Joel Sendek New Buy -1% $7.74
Sendek set a $10 target. He expects ARQL to begin Phase II testing next month of ARQ 197, a small molecule inhibitor of c-Met receptor tyrosine kinase, to treat solid tumors.
Auxilium (AUXL) Banc of America Securities William Ho Price...

Read the full 1175 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >